Prosensa notably higher on the day

|About: Prosensa Holding N.V. (RNA)|By:, SA News Editor

Shares of Prosensa (RNA +6.4%) are higher on the session.

Investors may be reacting to Adam Feuerstein's mention of the company in his article regarding the FDA's stance on DMD drugs.

"Chew's letter, suggests some wiggle room for the possibility that FDA would... might... possibly... be willing to review [Sarepta's] eteplirsen based on the existing phase II data," Feuerstein writes, before saying that "the same could be said for [RNA] and GSK's drisapersen, if the companies decide to submit data from the failed Phase 3 study."